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Conclusion.— The results of this clinical trial could lead to profound modiﬁcation of the man-
agement of aortic risk and complications in patients with Marfan syndrome and possibly in
MOTS CLÉS
Syndrome de Marfan ;
Aorte ;
Anévrisme de l’aorte
thoracique ;
Antagoniste des
récepteurs de
l’angiotensine II ;
TGF-beta
la pathologie aortique et ses complications chez les patients présentant un syndrome de Marfan
mais aussi possiblement dans la prise en charge des anévrismes aortiques thoraciques d’autres
. Tous droits réservés.
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ackground
arfan syndrome: deﬁnition
arfan syndrome (MFS) is an autosomal dominant disorder
ith pleiotropic features, including skeletal abnormalities,
ctopia lentis and aortic root dilatation. The main causal
ene for MFS is FBN1, encoding ﬁbrillin-1, a large glycopro-
ein that is a main component of extracellular microﬁbrils.
rognosis is determined mainly by aortic complications (dis-
ection or death), after progressive dilatation of the aortic
oot. Diagnosis criteria have changed over time; interna-
ional criteria were proposed in 1988 and reﬁned in 1996, to
ncrease speciﬁcity and to integrate genetic testing [1,2].
he current nosology is based on the Ghent criteria, which
eﬁne major and minor manifestations in different systems
Table [not provided]) [2]. In this setting, the diagnosis of
FS requires at least two major criteria and the involve-
ent of at least one other body system (i.e., three criteria
n total). In the presence of an FBN1 mutation or when MFS
s diagnosed in a ﬁrst-degree relative, only one major crite-
ion and the involvement of another body system is required
t
f
o
r
o2]. These Ghent criteria have excellent speciﬁcity for FBN1
utation recognition, because its detection is possible in
5% of patients who fulﬁl these criteria [3]. However, a
utation in the FBN1 gene is not pathognomonic of MFS
nd may generate a large array of phenotypes that over-
ap with MFS (familial ectopia lentis, Shprintzen-Goldberg
yndrome, other ﬁbrillinopathies) [4]. On the other hand,
ome features of MFS can also be present in patients with
utations in the gene coding for transforming growth fac-
or beta (TGF) receptor 2 (TGFBR2), who present with MFS
ype 2 [5—7]. Lastly, mutations in the gene coding for TGF
eceptor 1 (TGFBR1) may also lead to overlapping syndromes
3]. Therefore, deﬁning clear frontiers for MFS, fulﬁlling
he Ghent criteria and differentiating from other clinical
onditions that overlap with MFS (MFS type 2, Loeys-Dietz
yndrome, familial thoracic aortic aneurysm, Ehlers-Danlos
ascular syndrome [8—10]) can sometimes be challenging. In
he near future, a revised nosology will emerge, which willD. Detaint et al.
Summary
Background.— Recent studies have demonstrated that blockade of the angiotensin II type 1
receptor with losartan decreases aortic damage in an animal model of Marfan syndrome (a KI
mouse model with a pathogenic mutation in the gene coding for ﬁbrillin-1).
Aims.— To demonstrate a beneﬁcial effect of losartan on aortic dilatation when added to
optimal therapy in patients with Marfan syndrome.
Methods.— This is a multicentre, randomized, placebo-controlled, double-blind, clinical trial
with a 2-year inclusion period and a 3-year follow-up period. Aortic root diameter will be
measured using two-dimensional echocardiography. Secondary endpoints will include incidence
of aortic dissection, aortic root surgery, death, quality of life, tolerance and compliance with
treatments. We aim to enrol a total of 300 patients aged≥ 10 years who fulﬁl the Ghent criteria
for Marfan syndrome. Analyses will be based on intention to treat.patients with thoracic aortic aneurysms of other aetiologies.
© 2010 Elsevier Masson SAS. All rights reserved.
Résumé
Contexte.— Le losartan limite la dilatation aortique sur un modèle de souris KI, porteuse d’une
mutation pathogénique du gène FBN1, codant pour la ﬁbrilline de type 1.
But de l’étude.— Montrer le bénéﬁce du losartan ajouté au traitement optimal chez des
patients présentant un syndrome de Marfan.
Méthodes.— Étude randomisée, contre placebo, en double insu, avec une période d’inclusion
de deux ans et de trois ans de suivi. Le diamètre aortique est mesuré par échographie bidimen-
sionnelle. Les critères secondaires sont l’incidence des décès, de la dissection aortique, de la
chirurgie aortique, la qualité de vie, la tolérance et la compliance au traitement. Trois cent
patients devraient être inclus (patients de plus de dix ans remplissant les critères de Ghent).
L’analyse sera effectuée en intention de traiter.
Conclusion.— Les résultats de cette étude pourraient conduire à modiﬁer la prise en charge deocus on the features and criteria that distinguish MFS from
ther disorders; in the meantime, however, the Ghent crite-
ia remain the reference and will be used for classiﬁcation
f patients in the current study.
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Figure 1. Beneﬁcial effect of beta-blocker therapy on the aortic
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Current medical management
The aortic root diameter at the sinuses of Valsalva is
considered to be the best predictor of the occurrence
of an aortic event [11]. Patients with an absolute aortic
diameter > 50mm, an aortic ratio > 1.3 (observed/expected
diameters) or a z score > 3 (the z score is the number of
standard deviations above the mean) are considered at high
risk for catastrophic complications, based on data obtained
more than 10 years ago, before the publication of the Ghent
criteria [12]. In addition, rapid growth of the aortic root
(> 0.5 cm/year) and a family history of dissection are also
predictors of poor outcome in patients with MFS. Therefore,
routine monitoring of the aortic diameter is necessary for
determining the best time for surgery.
Associated medical therapy is mandatory and includes
avoidance of isometric exercises, sports limitation and
preventive medical therapy with beta-blockers or calcium
channel blockers, inducing bradycardia [13]. Indeed, the use
of beta-adrenergic blockade to decrease the haemodynamic
stress on the ascending aorta has been suggested since the
1970s [14]. The ﬁrst randomized, open-label trial was pub-
lished in 1994 [15] (Fig. 1). In this study, the rate of change
of aortic root diameter and clinical outcomes (aortic regur-
gitation, aortic dissection, surgery, heart failure and death)
were compared between 32 patients assigned randomly to
receive propanolol and 38 controls. At baseline, the abso-
lute aortic diameters were larger in the treated group than
in the non-treated group (34.6 vs 30.2mm) but the aortic
ratios (observed/expected diameters) were similar (1.4 vs
1.3, not signiﬁcant). After a decade of follow-up, the mean
change in aortic ratios over time was signiﬁcantly lower
in the treatment group (0.023/year) than in the control
group (0.084/year). No statistically signiﬁcant difference
was observed between groups in event-free survival, but the
rate of clinical events was higher in the control group than in
the treatment group. Retrospective studies in children have
demonstrated the beneﬁcial role of beta-blockers [16,17],
with a reduction in the rate of change in aortic diameter
of 0.16mm/year and a decrease in the number of aortic
complications [16].
From a theoretical point of view, the efﬁcacy of beta-
blockers relies on their haemodynamic properties, reducing
the force of left ventricular ejection (i.e., dp/dt) by
negative inotropy and the number of impulses due to brady-
cardia, particularly during stress and exercise. Most series
also demonstrate an increase in indexes of arterial wall
compliance (which is basically decreased in patients with
MFS [18]) with beta-blockers [19—21]. Nevertheless, the
absence of an increase in aortic compliance with beta-
blocker therapy has been observed in patients with marked
aortic enlargement or increased weight, stressing the impor-
tance of starting treatment early in the course of the
disease, with dose optimization [22—24].
Marfan syndrome in 2010: physiopathologyIn MFS, histological observations of the aortic wall classi-
cally show medial degeneration, with smooth muscle cell
disappearance, disorganization of elastic ﬁbres and accumu-
lation of mucopolysaccharides. These abnormalities are not
speciﬁc to MFS, as they can be observed in the aortic wall
s
m
p
t
ooot diameter (from Shores et al. [15]). The Y-axis represents the
atio of observed aortic diameter/normal aortic diameter. Arrows
orrespond to patients not taking the drug.
f aneurysms with other aetiologies, such as those related
o bicuspid aortic valves or even degenerative aneurysms
25—27].
These histological abnormalities led to hypotheses being
enerated on the pathogenesis of MFS aortic disease. Muta-
ions in the FBN1 gene encoding ﬁbrillin-1 result in an
bnormal protein and enhanced proteolytic degradation of
brillin-1. This protein is an essential component of the
icroﬁbrils that play a role in extracellular matrix structure
nd regulation, elastic ﬁbre organization and cell adhe-
ion [28]. Hence, the presence of structurally abnormal
icroﬁbrils would weaken the extracellular matrix, allowing
rogressive aortic dilatation. In this hypothesis, all fea-
ures associated with MFS are secondary to the weakening
f the extracellular matrix in different tissues, leading
320 D. Detaint et al.
Figure 2. Relationship between transforming growth factor beta (TGF)-binding protein and extracellular microﬁbrils (from Isogai et al.
[31]). TGF is synthesized as a precursor molecule containing a propeptide region. After it is synthesized, the TGF homodimer interacts
with a latency-associated peptide (LAP; a protein derived from the N-terminal region of the TGF gene product), forming a complex called
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M‘small latent complex’’. This complex remains in the cell until it
orming a larger complex called ‘‘large latent complex’’. This com
o increased growth of bones, hernia, cutaneous striaes,
tc.
Alternative hypothesis have been proposed, however,
ased on observations made in a mouse model of MFS,
hich carries a pathogenic mutation in FBN1 [29]. In this
odel, markers for activation of the TGF pathway (i.e.,
-smad-2) were present in smooth muscle cells, suggest-
ng activation. TGF molecules are cytokines, synthesized
nd secreted by smooth muscle cells as inactive precur-
ors in the form of a large latent complex (that includes a
ro-TGFmolecule and the ‘‘large TGF-binding protein’’),
hich is stored in the extracellular matrix [30]. One pro-
osed hypothesis is that abnormal ﬁbrillin causes failure of
he latent complex sequestration and excessive activation
31,32] (Fig. 2). Excessive TGF signalling would then cause
ncreased smad-2 phosphorylation and nuclear localization,
esulting in altered gene expression (Fig. 3).
xperimental therapy
xperimental studies in the KI mouse have shown an absence
f development of aortic aneurysm or myxomatous mitral
alve in animals treated with TGF antibodies [33,34]. Inter-
stingly, a similar effect has been observed with the use of
osartan, a blocker of the angiotensin II type 1 receptor (AT1)
33]. Indeed, AT1 stimulation with angiotensin II activates
he process of ﬁbrosis and cell proliferation. These effects
re mediated by TGF activation.
In the experimental study by Habashi et al. [33], com-
arison of aortic diameter growth between Marfan mice
reated with placebo, propanolol or losartan showed that
a
t
t
r
cnd by another protein called latent TGF-binding protein (LTBP),
s secreted to the extracellular matrix.
oth beta-blockers and AT1 blockers (angiotensin II type 1
eceptor blockers [ARBs]) reduced the rate of change in aor-
ic diameter compared with placebo. However, regarding
he histological abnormalities, only treatment with losartan
educed the disarray of the extracellular matrix signiﬁ-
antly.
The primary results of non-randomized and small studies
n humans are encouraging. Brooke et al. [35] compared the
rogression of aortic root diameter in 18 children with MFS,
efore and after treatment with ARBs. After treatment with
RBs in addition to beta-blockers over 2 years, the rate of
hange of the Valsalva and sinotubular junction decreased
igniﬁcantly from 3.5mm/year to 0.46mm/year. However,
his study had many limitations, including its retrospective
ature, the selection of children at the time of maximal
ortic growth, the absence of a control group of any kind
nd the normalization of the aortic diameter using unusual
ules.
Although this hypothesis is very appealing, some unex-
lained results have been observed. Firstly, blocking only
T1, ARBs allow beneﬁcial effects (ﬁbrosis and cell pro-
iferation inhibition) via signalling through the angiotensin
I type 2 receptor (AT2), whereas angiotensin-converting
nzyme inhibitors (ACEIs) reduce both AT1 and AT2 sig-
alling. Ahismatos et al. [36] randomized 17 adults with
FS to receive either an ACEI (perindopril) or placebo in
ssociation with beta-blocker therapy. The study showed
hat, after 6 months, the stiffness of the aorta and the aor-
ic root diameters had decreased signiﬁcantly in patients
eceiving the ACEI and the aortic diameter became smaller
ompared with placebo. Levels of TGF were reduced by
Marfan Sartan study
Figure 3. The transforming growth factor beta (TGF) signalling
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years) and existence (or not) of ongoing prophylactic therapypathway (modiﬁed from ten Dijke and Arthur [42]). ALK5: trans-
forming growth factor beta receptor 1; TGFBR2: transforming
growth factor beta receptor 2.
ACEI therapy, suggesting that ACEIs, like ARBs, target the
underlying tissue pathology, in addition to reducing haemo-
dynamic stress. These results, obtained in only one centre in
a very small number of patients (10 receiving placebo, seven
receiving perindopril) will have to be reproduced by others
before being accepted widely. However, they are supported
by non-randomized data [37].
Secondly, the presence of p-samd-2 in smooth muscle
cells has been observed in the aortic wall of patients with a
TGFBR2 mutation blocking transmission of the signal and in
aneurysms of various aetiologies; this is compatible with the
release of TGF by the matrix when it is destroyed, regard-
less of the aetiology of the extracellular matrix alteration
[27].
Hence the beneﬁt of blockade of the renin-angiotensin
system seems promising in MFS, but has not been demon-
strated in humans. Multicentre trials are needed to address
this question. A trial designed to test the efﬁcacy of losar-
tan vs atenolol is ongoing in the USA [38] and aims to include
604 patients (children and adults). Another three-arm Italian
trial is ongoing to evaluate the effect of losartan vs nebivolol
vs a combination of both on the progression of aortic root
dilatation [39].
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ationale for this trial
e have initiated this trial to evaluate the safety and ben-
ﬁt of losartan on aortic root growth in MFS when added to
ccepted standard therapy. Beta-blocker therapy has lim-
tations (merely a haemodynamic effect, lack of target in
he underlying tissue pathology, side effects), but remains
he standard of medical care in MFS. Therefore, consider-
ng a trial without allowing beta-blocker therapy might be
erceived to be unethical. Besides, while beta-blockers are
xerting their haemodynamic effects, losartan should mod-
fy the physiology within the aortic wall; in other words,
he pathophysiology indicates that their effects should be
dditive.
ethods
tudy design
ypothesis and overview
his trial is designed to test the hypothesis that the addition
f ARB therapy (losartan) to optimal standard therapy will
educe the rate of aortic dilatation compared with placebo
n MFS patients aged≥ 10 years. The decision to include
ounger patients rather than just adults derives from the
ore rapid aortic root dilatation progression during growth
nd the fact that demonstration of beneﬁt in a mouse model
as obtained in young individuals.
opulation
nclusion criteria
he inclusion criteria for this study are as follows: age≥ 10
ears; diagnosis of MFS according to Ghent criteria, with
r without known FBN1 mutation; informed consent and
ssent of participant, and parent(s) or legal guardian, as
pplicable. Patients will be excluded from the study for
he following reasons: prior or planned aortic root surgery;
nability to obtain accurate measurement of aortic root due
o poor acoustic windows with transthoracic echocardiog-
aphy; contraindication to losartan (bilateral renal artery
tenosis, history of angio-oedema while taking ARB therapy);
actose intolerance, galactosaemia, or glucose or galactose
alabsorption; pregnancy or planned pregnancy within 36
onths of enrolment; absence of medical insurance (Secu-
ité sociale or Couverture maladie universelle).
andomization and stratiﬁcation
ligible subjects will continue their standard prophylac-
ic therapy (beta-blocker [or calcium channel blocker if
eta-blocker therapy is not tolerated]) and will be assigned
andomly to receive either losartan or placebo. Randomiza-
ion will assign losartan or placebo in a 1:1 ratio and will
e stratiﬁed according to centre, age at inclusion (< or≥ 18beta-blocker or calcium channel blocker). The randomiza-
ion code will not be available to the investigators by any
eans, ensuring double-blind assignment.
322 D. Detaint et al.
Table 1 Scheduled examinations at each visit.
Examination Timing
Day 0 Day 15 Month 6 Month 12 Month 18 Month 24 Month 30 Month 36
Informed consent signed ×
Randomization ×
Clinical examination × × × × × × ×
Complete medical history ×
SF-36 quality of life questionnaire × × × × × × ×
Laboratory testing
Creatinine concentration,
uraemia, kalaemia
× × × × ×
Pregnancy test ×
Echocardiography × ×
Treatment distribution × ×
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cigure 4. Methods of aortic root measurement using two-
imensional echocardiography (parasternal view) (from Roman et
l. [40]). Ao: aorta; OG: left atrium; VG: left ventricle.
ollow-up
ollow-up visits are scheduled every 6 months (Table 1)
nd include: clinical examination; questions about adverse
rug reactions; SF-36 quality of life questionnaire; echocar-
iography; laboratory testing, including creatinine plasma
oncentration, uraemia and kalaemia (annually).
The aortic root diameter will be measured using transtho-
acic echocardiographic pictures or sequences recorded by
rained echocardiographers according to recommendations
40] (Fig. 4).
ndpointshe primary endpoint is the rate of change in aortic root
iameter (sinuses of Valsalva), normalized to its theoret-
cal value (expressed as z-score per year). The secondary
ndpoints include: rate of change in aortic root diame-
er with absolute dimension (expressed in mm per year);
T
T
m× × × × ×
× × × ×
ortic complications (aortic root surgery, aortic dissection,
ardiac death, death); compliance with treatment (inci-
ence of adverse drug reactions reported during routine
urveillance [hypotension, syncope]; compliance with losar-
an [proportion of patients taking at least 80% of pills given];
ompliance with beta-blockers based upon patient’s decla-
ation); evaluation of quality of life based upon the SF-36
uestionnaire.
tatistical considerations
ample size
he sample necessary to verify the hypothesis has been cal-
ulated using data obtained from Shores et al. [15]. In this
tudy, which compared the rate of aortic root dilatation in
atients receiving beta-blockers vs no treatment, the rate of
ortic root dilatation was 0.084 /year without treatment vs
.0253 /year with beta-blockers (around four times lower)
nd the maximum standard deviation was 0.03.
The sample size calculation was based on the assumption
hat losartan efﬁcacy in patients already receiving pro-
hylactic therapy will be half of the beta-blocker efﬁcacy
0.01), and on the comparison of losartan with placebo with
.80 power and a two-sided  of 0.05. To account for poten-
ial patient dropout, a total of 150 patients will be required
n each group.
nalyses
nalyses will be performed on an intention-to-treat
asis. Baseline characteristics will be summarized as
eans± standard deviations and percentages, and com-
ared between the two arms of the trial using the chi-square
est or analysis of variance. As a supplementary analysis,
he mortality rate or event-free survival will be compared
sing the log-rank test. The signiﬁcance level will be 0.05.
or the primary endpoint, the ﬁnal analysis will compare
he mean slope of aortic dilatation between groups with
ovariate-adjusted analysis and after 3 years of follow-up.rial organization and timeline
he Assistance publique—Hôpitaux de Paris and the départe-
ent de recherche clinique et du développement will be
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responsible for all aspects of the study. The protocol has
been approved by the Agence franc¸aise de sécurité sanitaire
des produits de Santé and by a safety committee (Comité de
protection des personnes).
Enrolment began in September 2008; by mid-April 2010
more than 200 subjects had been enrolled. All centres will
follow the same study procedure.
The trial has been declared on clinicaltrial.gov
(NCT00763893).
Discussion
Choice of primary endpoint
Our primary endpoint is the rate of change in aortic root
diameter normalized to its theoretical value. This choice is
based on the relationship between aortic root dimensions
and outcome, namely aortic complication, and therefore
prophylactic intervention. Aortic root diameters are also
easily measured by transthoracic echocardiography, with
good reproducibility. Furthermore, from a statistical point
of view, the primary endpoint is a continuous variable, which
is more powerful than a quantitative variable for identify-
ing a potential difference between groups. Moreover, it was
used previously for the evaluation of beta-blocker therapy in
1994 [15] and, more recently, for the evaluation of losartan
[33,35].
Our decision to compare normalized diameters and not
absolute diameters was due to the relationship between aor-
tic diameter and body surface area, which is very variable.
Using the normalized diameter should decrease variability
and therefore increase the power of the study to detect
a difference. Randomization should result in two similar
groups, reducing differences in body size between groups
and allowing comparison of the changes in mean absolute
diameter (our second endpoint). We recognize that differ-
ent normalizations exist in the literature, and we planned
to use, like most teams, standardization according to the
nomogram publication by Roman et al. [40]. However, we
recently published new nomograms for children [41].
Implication for future management of Marfan
syndrome
If demonstration of safety and efﬁcacy of losartan in asso-
ciation with beta-blocker therapy can be obtained in this
double-blind, randomized trial, standard care of these
patients will be modiﬁed. Until the results are obtained,
however, the standard care remains beta-blocker therapy,
as a few differences can be identiﬁed between a KI mouse
model with one FBN1 mutation and humans with MFS. Firstly,
in the mouse model, only one mutation has been evaluated,
and this mutation has been associated with only one genetic
background (all the mice have the same genotype). In con-
trast, in humans, each family carries its own mutation or
almost so (private mutations), and the genetic background
differs from one individual to another, which is responsible
for the unique aspect of each human. It is not clear that all
mutations will act through the same mechanism (negative
dominance vs haploinsufﬁciency), and the effect of a given
mutation is probably highly dependent on the genetic back-
s
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round, as suggested by the great clinical variability of MFS
everity within one family (modiﬁer genes).
Besides, compliance may be an issue for a drug given
ong-term; while tap water is an absolute necessity for mice,
aking an additional pill is optional for patients. Side effects
ay occur that may further limit the compliance of patients
including hypotension, which gives an increased perception
f fatigue). These factors are crucial for drugs that have to
e taken for life.
It is impossible, therefore, to conclude before the results
f the ongoing randomized trials are available, whether the
rescription of losartan is useful in patients with mutations
n the FBN1 gene.
omparison of ongoing trials
he USA trial is comparing beta-blocker therapy (atenolol)
irectly with losartan in an open-label, randomized trial
38]. This study evaluates the advantages of two differ-
nt ﬁrst-line therapies but not the beneﬁt of combining
he two drugs compared with up-to-date standard therapy.
esides, in this protocol, the criteria chosen for optimizing
eta-blocker therapy are not in keeping with usual care in
uropean countries, including France (up-titration based on
4-hour electrocardiogram and mean dose of beta-blockade
igher than that used in France).
The Italian trial is comparing three different approaches
irectly: beta-blocker or losartan or both [39]. The
eta-blocker being used (nebivolol) carries theoretical
dvantages over the non-selective propanolol used in the
andmark study of Shores et al. [15], and over the beta-
locker used in the USA trial (atenolol): its vasodilatory
roperties could decrease the rebound wave and therefore
he stress applied on the proximal aorta and enhance the
aemodynamic beneﬁt of the drug; its beta-1 selectivity
hould increase its tolerance and therefore compliance. The
RB being used also allows 1-day administration and opti-
al receptor blockade. Lastly, the relative beneﬁts of the
wo classes of drug and their combination are ideal. The
rawback of having three groups is the necessity for a high
umber of patients to obtain the statistical power to be able
o recognize differences between groups.
Lastly, the University of Ghent has also started a random-
zed trial with a design similar to ours, but also evaluating
he evolution of aortic stiffness over time. The similar design
ay allow secondary combination of the populations to
ncrease statistical power, which is obviously an issue when
he protocol aims to include such a selected population.
hich population may beneﬁt from the
esults?
n current medical practice, beta-blocker therapies are
roposed for patients with ascending aorta aneurysms of
arious aetiologies, based on haemodynamic concept and
he randomized trial completed in the population with MFS.
e reported recently that similarities in the pathogene-is of aortic aneurysms of varying aetiologies, including
ncreased p-smad-2 (a marker for TGF activation), have
een observed [27]. Therefore, if slowing of aortic dilatation
an be demonstrated in patients with MFS with AT1 block-
de, the question of the applicability of the ﬁndings to a
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arger population (i.e., all aortic aneurysms) will obviously
rise. Similarly, AT1 blockade may become the ﬁrst-line
edical therapy in hypertension associated with conditions
nown to be at risk of development of aneurysm of the
scending aorta (e.g. bicuspid aortic valve, coarctation of
he aorta).
imitations
ur study will not be able to evaluate the superiority of
ne therapy over the other. However beta-blocker therapy
s the standard of care for patients with MFS and the current
tudy will evaluate the efﬁcacy of losartan in addition to this
rophylactic standard therapy.
The study results may not be extrapolated to children
ged younger than 10 years and to variants of MFS who do
ot meet the Ghent criteria.
onclusions
he rationale behind a trial of losartan therapy in addi-
ion to standard beta-blocker therapy in MFS is strong and
s based on recent advances in the understanding of the
isease pathogenesis. The results should establish if the ben-
ﬁts demonstrated in the mouse model are applicable to
umans or if other strategies should be looked for. If strong
vidence of a treatment beneﬁt for ARBs in patients with
FS can be obtained, the natural history of MFS and aortic
neurysms with other aetiologies may change dramatically
n the future.
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